LYN inhibitors(Tyrosine-protein kinase Lyn inhibitors), PDGFRα inhibitors(Platelet-derived growth factor receptor alpha inhibitors), PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases+ [6]

Active Indication

Amyotrophic Lateral SclerosisMultiple SclerosisMelanoma+ [6]

Inactive Indication

Alzheimer DiseaseAsthmaCrohn Disease+ [20]

Originator Organization

AB Science SA

Active Organization

AB Science SA

Inactive Organization-

Drug Highest PhaseNDA/BLA

First Approval Date-

RegulationOrphan Drug (US), Orphan Drug (EU), Orphan Drug (CH)

Structure

Molecular FormulaC29H34N6O4S2

InChIKeyTXCWBWKVIZGWEQ-UHFFFAOYSA-N

CAS Registry1048007-93-7

107

Clinical Trials associated with Masitinib mesylate

NCT05564169 / Not yet recruitingPhase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study of Masitinib as add-on Therapy in Patients With Mild to Moderate Alzheimer's Disease

Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

Start Date01 Jan 2024

Sponsor / Collaborator

AB Science SA

NCT05449444 / RecruitingPhase 2

A 24-week, Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-range Finding Phase II Study to Compare Efficacy and Safety of Oral Masitinib to Placebo in Treatment of Patients With Severe Mast Cell Activation Syndrome (MCAS) With Handicap Unresponsive to Optimal Symptomatic Treatment

To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.

Start Date01 Jul 2022

Sponsor / Collaborator

AB Science SA

NCT05441488 / RecruitingPhase 3

A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse

To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.

Start Date28 Jun 2022

Sponsor / Collaborator

AB Science SA

100 Clinical Results associated with Masitinib mesylate

100 Translational Medicine associated with Masitinib mesylate

100 Patents (Medical) associated with Masitinib mesylate

176

Literatures (Medical) associated with Masitinib mesylate

01 Feb 2024·Ageing research reviews

Navigating the dementia landscape: Biomarkers and emerging therapies

Review

Author: Akhtar, Juber ; Ansari, Vaseem Ahamad ; Verma, Amita ; Maheshwari, Shubhrat ; Singh, Aditya ; Mahmood, Tarique ; Wasim, Rufaida

The field of dementia research has witnessed significant developments in our understanding of neurodegenerative disorders, with a particular focus on Alzheimer's disease (AD) and Frontotemporal Dementia (FTD). Dementia, a collection of symptoms arising from the degeneration of brain cells, presents a significant healthcare challenge, especially as its prevalence escalates with age. This abstract delves into the complexities of these disorders, the role of biomarkers in their diagnosis and monitoring, as well as emerging neurophysiological insights. In the context of AD, anti-amyloid therapy has gained prominence, aiming to reduce the accumulation of amyloid-beta (Aβ) plaques in the brain, a hallmark of the disease. Notably, Leqembi recently received full FDA approval, marking a significant breakthrough in AD treatment. Additionally, ongoing phase 3 clinical trials are investigating novel therapies, including Masitinib and NE3107, focusing on cognitive and functional improvements in AD patients. In the realm of FTD, research has unveiled distinct neuropathological features, including the involvement of proteins like TDP-43 and progranulin, providing valuable insights into the diagnosis and management of this heterogeneous condition. Biomarkers, including neurofilaments and various tau fragments, have shown promise in enhancing diagnostic accuracy. Neurophysiological techniques, such as transcranial magnetic stimulation (TMS), have contributed to our understanding of AD and FTD. TMS has uncovered unique neurophysiological signatures, highlighting impaired plasticity, hyperexcitability, and altered connectivity in AD, while FTD displays differences in neurotransmitter systems, particularly GABAergic and glutamatergic circuits. Lastly, ongoing clinical trials in anti-amyloid therapy for AD, such as Simufilam, Solanezumab, Gantenerumab, and Remternetug, offer hope for individuals affected by this devastating disease, with the potential to alter the course of cognitive decline. These advancements collectively illuminate the evolving landscape of dementia research and the pursuit of effective treatments for these challenging conditions.

15 Sep 2023·Molecules (Basel, Switzerland)

Development of Masitinib Derivatives with Enhanced M^pro Ligand Efficiency and Reduced Cytotoxicity.

Article

Author: Mohamed, Adil ; Tay, Savaş ; Perez-Lemus, Gustavo R ; Rawe, Benjamin W ; Menendez, Cintia A ; Byléhn, Fabian ; de Pablo, Juan J ; Liu, Guancen ; Mendels, Dan ; Kenna, Emma ; Alvarado, Walter ; Weiss, Adam M ; Rowan, Stuart J ; Crolais, Alex E

Recently, a high-throughput screen of 1900 clinically used drugs identified masitinib, an orally bioavailable tyrosine kinase inhibitor, as a potential treatment for COVID-19. Masitinib acts as a broad-spectrum inhibitor for human coronaviruses, including SARS-CoV-2 and several of its variants. In this work, we rely on atomistic molecular dynamics simulations with advanced sampling methods to develop a deeper understanding of masitinib's mechanism of M^pro inhibition. To improve the inhibitory efficiency and to increase the ligand selectivity for the viral target, we determined the minimal portion of the molecule (fragment) that is responsible for most of the interactions that arise within the masitinib-M^pro complex. We found that masitinib forms highly stable and specific H-bond interactions with M^pro through its pyridine and aminothiazole rings. Importantly, the interaction with His¹⁶³ is a key anchoring point of the inhibitor, and its perturbation leads to ligand unbinding within nanoseconds. Based on these observations, a small library of rationally designed masitinib derivatives (M1-M5) was proposed. Our results show increased inhibitory efficiency and highly reduced cytotoxicity for the M3 and M4 derivatives compared to masitinib.

01 Sep 2023·Arabian journal of chemistry

A suitable drug structure for interaction with SARS-CoV-2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study.

Article

Author: Mir, Amirabbas ; Mahani, Mohamad ; Dashti, Razieh ; Montazer, Leila ; Yoosefian, Mehdi

In recent years, more than 200 countries of the world have faced a health crisis due to the epidemiological disease of COVID-19 caused by the SARS-CoV-2 virus. It had a huge impact on the world economy and the global health sector. Researchers are studying the design and discovery of drugs that can inhibit SARS-CoV-2. The main protease of SARS-CoV-2 is an attractive target for the study of antiviral drugs against coronavirus diseases. According to the docking results, binding energy for boceprevir, masitinib and rupintrivir with CMP are -10.80, -9.39, and -9.51 kcal/mol respectively. Also, for all investigated systems, van der Waals and electrostatic interactions are quite favorable for binding the drugs to SARS-CoV-2 coronavirus main protease, indicating confirmation of the complex stability.

News (Medical) associated with Masitinib mesylate

28 Jun 2024

·www.globenewswire.com

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 28 June, 2024, 12:30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS). AB Science intends to ask for re-examination on the basis of: 1) First and foremost, the urgent need for patients to have early access to a promising treatment. 2) The opportunity of having the dossier re-examined by new rapporteurs and by a Scientific Advisory Board. AB Science highlights the difficulty of a conditional marketing authorization in ALS and cannot guarantee a positive outcome following this re-examination. The grounds to request a re-examination could be based on the following elements: Acceptable masitinib safety: First, the CHMP confirmed that the safety of masitinib is deemed acceptable, which is a key consideration in the context of a conditional marketing authorization where confirmatory evidence of efficacy is required.Objection concerning deviations from Good Clinical Practice: As per EMA guidance (EMA/868942/2011), impact analyses of all protocol deviations that could not be corrected were performed and showed no impact, resolving Good Clinical Practice issues as per guideline.Objection concerning the exclusion of fast progressors: The amendment transitioning from phase 2 to phase 3 excluding fast progressors from the primary analysis population was necessary and well justified, in order to have a more homogenous population with greater chance of reaching week 48 time point and minimizing missing data. Furthermore, the amendment was implemented early enough and while the study was blinded, removing any methodological issues.Objection concerning the treatment of missing data in the primary analysis: Multiple sensitivity analysis of the primary analysis; using non LOCF (Last Observation Carried Forward) methods for imputation of missing data, are positive and consistent, including two analyses previously recommended by the CHMP, demonstrating the robustness of the primary analysis, thus resolving the objection concerning the treatment of missing data.Objection on the subgroup data: There was an important imbalance in a subset of patients experiencing complete loss of function (i.e., ALSFRS-R score of zero) in one or more of the item scores (20% in the masitinib arm versus 8% in the placebo arm), because ALSFRS-R score was minimized but not stratified by category of severity. The subgroup defined as patients prior to any complete loss of function (i.e. excluding the overmentioned biased subset) accounted for 86% of the population and showed extremely compelling results, including a significant 12 months survival benefit. The subgroup analysis is the strict application of EMA guidance (EMA/CHMP/539146/2013), which is applicable to post hoc analysis and to registration with single pivotal study, thus resolving the objection regarding subgroup data. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science’s website: www.ab-science.com. Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ab-science.com Attachment CP UPDATE ALS EMA VENG VF

Clinical ResultPhase 3

31 May 2024

·www.globenewswire.com

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS). The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ The presentation covered three topics: Conditional approval of masitinib in ALS with the European Medicines Agency (EMA)Conditional approval of masitinib in ALS with Health CanadaAvailable preclinical and clinical data in the context of a full approval Regarding the conditional approval of masitinib in ALS with EMA, AB Science presented the CHMP trend vote position, concluding that the safety of masitinib is deemed acceptable but outstanding issues remain preventing a favorable benefit assessment. These issues and main justifications presented by AB Science are detailed in the presentation. The EMA decision will be made public during the next CHMP meeting to be held on June 24-27, 2024. As a next step, AB Science indicated that it has the option to request a re-examination, and that it would liaise with the EMA to define the appropriate pathway to registration. In case of re-examination, a new Rapporteur and new Co-Rapporteur are appointed to assess the dossier, and a Scientific Advisory Group) can be appointed to provide recommendations on key points. Such key points could include: Application of EMA guideline on the Good Clinical Practices (GCP), application of EMA guideline on subgroup, application of the two recommendations for handling of missing data, and whether excluding Fast progressors from primary analysis is justified. Regarding the conditional approval of masitinib in ALS with Health Canada, AB Science presented the main clinical objections raised by Health Canada, which were slightly different from the ones raised by EMA. Finally, AB Science clarified that a distinction was to be made between the conditional marketing authorization that requires very compelling evidence from a single study, and the available preclinical and clinical data from masitinib program, that are robust and will support full approval, provided a confirmatory study is positive. Masitinib has a validated mechanism of action, targeting the innate immune system, via modulation of mast cells and microglia. Masitinib exerts a protective effect on the central nervous system and on the peripheral nervous system. In addition, Masitinib has demonstrated its ability to lower blood levels of neurofilament light (NfL) in a neurodegenerative disease model (EAE model).Study AB10015 is a 48-week study, which is stronger evidence than a 24-week study, and is same time point as the confirmatory study. In addition, study AB10015 demonstrated a significant treatment effect in the primary analysis population.Data are exceptionally strong in the population close to the confirmatory study and that could be the claim, with a significant benefit on functional score, a significant benefit on quality of life, and a significant benefit of plus 12 months on long-term overall survival. AB Science has asked to Euronext Paris to resume listing of its shares from the opening of trading on Monday June 03, 2024. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).Further information is available on AB Science’s website: www.ab-science.com. Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ab-science.com Attachment Summary Webcast May 30 2024 VENG VF

Drug ApprovalClinical Result

29 May 2024

·www.biospace.com

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following an oral explanation held at the 28 May meeting of the CHMP. The CHMP is expected to adopt a formal opinion on the MAA at its next meeting, which will be held June 24-27, 2024. AB Science will continue to work with the CHMP to determine the appropriate pathway forward, including a possible request for re-examination. AB Science will host a live webcast on Thursday May 30, 2024, from 5.30pm to 6.30pm CET. The agenda of this live webcast will be to explain the main clinical objections leading the CHMP not to consider approving at this time masitinib for treatment of ALS, and the arguments potentially justifying a request for re-examination. The presentation will be followed by a Q&A session. AB Science has asked Euronext to suspend the listing of its shares on the Euronext market, with effect from the publication of this press release, pending the publication of the press release summarizing the webcast. Webcast Information Webcast date: Thursday May 30, 2024. US: 11.30am-12.30pm ET; Europe: 5.30pm-6.30pm CET Access to the webcast (audio + presentation): Access to the webcast About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science’s website: . Forward-looking Statements - AB Science This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB Science Financial Communication & Media Relations investors@ab-science.com Attachment CP ALS REG EMA VENG VF

100 Deals associated with Masitinib mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Masitinib mesylate	L01XE22	DB11526

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	NDA/BLA	CA	AB Science SA	26 May 2022
Mastocytosis	NDA/BLA	EU	AB Science SA	14 Sep 2017
Gastrointestinal Stromal Tumors	NDA/BLA	EU	AB Science SA	-
Multiple Sclerosis	Phase 3	US	AB Science SA	29 Dec 2022
Asthma	Phase 3	AR	AB Science SA	01 Dec 2016
Asthma	Phase 3	MY	AB Science SA	01 Dec 2016
Asthma	Phase 3	PE	AB Science SA	01 Dec 2016
Asthma	Phase 3	PH	AB Science SA	01 Dec 2016
Asthma	Phase 3	UA	AB Science SA	01 Dec 2016
Melanoma	Phase 3	CN	AB Science SA	11 Aug 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02588677 (AB10015, AAN2023)	Phase 2/3	Amyotrophic Lateral Sclerosis Add-on	-	Masitinib 4.5 mg/kg/d	mktwszncju(xhkrbuoqse) = qqwupuuvym cafkuykcqb (zukugayaua )	-	25 Apr 2023
				Riluzole alone	mktwszncju(xhkrbuoqse) = yjhuuclbtw cafkuykcqb (zukugayaua )
NCT01433497 (Pubmed \| Neurol Neuroimmunol Neuroinflamm) Manual	Phase 3	Multiple Sclerosis	611	masitinib	muopzjhtsh(phrywlqbnr) = tkphlwgzqe hunmiagylg (zqmctckjkq )	Positive	21 Feb 2022
				Placebo	muopzjhtsh(phrywlqbnr) = qrnxbozyhu hunmiagylg (zqmctckjkq )
AUA2021	Phase 3	Metastatic castration-resistant prostate cancer First line	714	Masitinib 6.0 mg/kg/d plus DocetaxelMasitinib 6.0 mg/kg/d plus Docetaxel	axurmxkzlg(izvrjesfxq) = tclmgssoyy xnsvjvgzii (wdvdavobzj ) View more	Positive	01 Sep 2021
				Placebo plus Docetaxel	axurmxkzlg(izvrjesfxq) = omxakqlloo xnsvjvgzii (wdvdavobzj ) View more
NCT01872598 (AB09004, GlobeNewswire) Manual	Phase 3	Alzheimer Disease	358	Masitinib mesylate	atjfzkefri(gfzpckkqnh) = nhjxhehduz yotomsycbu (etmdoikgxk ) View more	Positive	29 Jul 2021
				Placebo	atjfzkefri(gfzpckkqnh) = npclxpaofx yotomsycbu (etmdoikgxk ) View more
NCT03766295 (AB12005, ASCO2021)	Phase 3	Pancreatic Cancer First line	384	Masitinib plus gemcitabine	xcyvxcggzj(jrkfhgckoh) = dzrulzfsge vpoefgiwuo (vrdzjplbby )	Positive	28 May 2021
				Placebo plus gemcitabine	xcyvxcggzj(jrkfhgckoh) = cxvbttxyzc vpoefgiwuo (vrdzjplbby )
NCT03761225 (AB12003, Corporate Publications) Manual	Phase 3	Castration-Resistant Prostatic Cancer First line	714	Docetaxel+Masitinib	vwtpnoswbf(uqhxjfdpgg) = omyamgnuvp uhfslyzeuf (cruvawejbr, 4.9 ~ 6.3) View more	Negative	25 May 2021
				Docetaxel+Placebo	vwtpnoswbf(uqhxjfdpgg) = wkzmsqibtx uhfslyzeuf (cruvawejbr, 4.9 ~ 5.9) View more
NCT01433497 (AB07002, ECTRIMS2020)	Phase 3	Multiple Sclerosis, Chronic Progressive	-	Masitinib 4.5 mg/kg/d	lmowtfvozg(sqdemzclhb): ΔLSM = -0.097 (95% CI, -0.192 to -0.002), P-Value = 0.0256 View more	Positive	07 Dec 2020
				Placebo
NCT03771040 (AB14001, GlobeNewswire) Manual	Phase 3	Severe asthma	-	masitinib	getftrdmrq(cbmhwrqses) = qtduyimajn nvamblzjuu (icbpqtvfza ) View more	Positive	20 Oct 2020
				Placebo	getftrdmrq(cbmhwrqses) = txkpvdffvm nvamblzjuu (icbpqtvfza ) View more
ERS2020	Phase 3	Severe asthma eosinophil count	-	Masitinib 6 mg/kg/d	lsrjzwifmz(onyhzbydjl): RR = 0.64 (95% CI, 0.47 - 0.9), P-Value = 0·0103	Positive	07 Sep 2020
				Placebo
ANA2017	Not Applicable	-	-	Masitinib 4.5mg/kg/day	blccaoploj(mhmnpmwjic) = Frequency of diarrhea with masitinib in this patient cohort was 24% yrqkpfnjrb (joryhvdunh ) View more	Positive	15 Oct 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis